Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Histidine Oral Supplementation for Alzheimer's Disease
NCT06169826Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of l-histidine in Alzheimer's disease (AD), sponsored by Wake Forest University Health Sciences. Planned start Apr 2025; status: withdrawn.
02
Drugs
l-histidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06169826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169826.